Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment.

Lukas JC, Calvo R, Zografidis A, Ortega I, Suárez E.

Biopharm Drug Dispos. 2010 Mar;31(2-3):129-37. doi: 10.1002/bdd.697.

PMID:
20155737
[PubMed - indexed for MEDLINE]
2.

Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.

Miao LY, Huang CR, Hou JQ, Qian MY.

Biopharm Drug Dispos. 2008 Jan;29(1):1-5.

PMID:
17941052
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.

Chueh SC, Wang SM, Lai MK, Chen J.

Transplant Proc. 2004 Sep;36(7):2058-9.

PMID:
15518745
[PubMed - indexed for MEDLINE]
4.

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.

Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.

Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1093-8.

PMID:
17042920
[PubMed - indexed for MEDLINE]
5.

Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.

Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, De Meyer M, Malaise J, Eddour DC, Lison D, Squifflet JP, Haufroid V.

Transplantation. 2005 Oct 15;80(7):977-84.

PMID:
16249748
[PubMed - indexed for MEDLINE]
6.

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.

Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, Legendre C, Thervet E.

Am J Transplant. 2005 Mar;5(3):595-603.

PMID:
15707415
[PubMed - indexed for MEDLINE]
Free Article
7.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P.

Pharmacogenetics. 2004 Mar;14(3):147-54.

PMID:
15167702
[PubMed - indexed for MEDLINE]
8.

Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.

Steigerwalt SP, Brar N, Dhungel A, Butcher D, Steigerwalt S, El-Ghouroury M, Provenzano R.

Transplant Proc. 2009 Dec;41(10):4184-7. doi: 10.1016/j.transproceed.2009.07.109.

PMID:
20005365
[PubMed - indexed for MEDLINE]
9.

A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.

Falck P, Midtvedt K, Vân Lê TT, Storehagen L, Holdaas H, Hartmann A, Asberg A.

Clin Pharmacokinet. 2009;48(9):615-23. doi: 10.2165/11313380-000000000-00000.

PMID:
19725595
[PubMed - indexed for MEDLINE]
10.

Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipients.

Wu FL, Tsai MK, Sun SW, Chen RR, Huang JD, Lee PH.

J Formos Med Assoc. 2005 Jan;104(1):22-8.

PMID:
15660173
[PubMed - indexed for MEDLINE]
11.

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.

Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group.

Transplantation. 2002 Dec 15;74(11):1560-7.

PMID:
12490789
[PubMed - indexed for MEDLINE]
12.

Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury.

Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S.

Transplantation. 2003 Dec 15;76(11):1594-9.

PMID:
14702530
[PubMed - indexed for MEDLINE]
13.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
[PubMed - indexed for MEDLINE]
14.

Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results.

Ferreira AN, Machado PG, Felipe CR, Motegi SA, Hosaka BH, Tanaka MK, Kamura LA, Park SI, Garcia R, Franco M, Alfieri F, Casarini DE, Tedesco-Silva H Jr, Medina-Pestana JO.

Clin Transplant. 2005 Oct;19(5):607-15.

PMID:
16146551
[PubMed - indexed for MEDLINE]
15.

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.

Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.

Pharmacogenet Genomics. 2008 May;18(5):413-23. doi: 10.1097/FPC.0b013e3282f9ac01.

PMID:
18408564
[PubMed - indexed for MEDLINE]
16.

Early sirolimus therapy in renal transplant recipients at high risk: is it justified?

Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.

Transplant Proc. 2009 Sep;41(7):2784-8. doi: 10.1016/j.transproceed.2009.07.015.

PMID:
19765435
[PubMed - indexed for MEDLINE]
17.

Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.

Azarpira N, Aghdaie MH, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhoseinie SA, Raisjalal GH, Rahsaz M, Pourgholami A, Sagheb F.

Exp Clin Transplant. 2006 Jun;4(1):416-9.

PMID:
16827636
[PubMed - indexed for MEDLINE]
Free Article
18.

De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.

Vincenti F, Stock P.

Transplant Proc. 2003 May;35(3 Suppl):183S-186S.

PMID:
12742494
[PubMed - indexed for MEDLINE]
19.

Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.

Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-Silva H Jr, Medina-Pestana JO.

Fundam Clin Pharmacol. 2009 Oct;23(5):625-31. doi: 10.1111/j.1472-8206.2009.00699.x. Epub 2009 Jul 28.

PMID:
19656203
[PubMed - indexed for MEDLINE]
20.

Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.

Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.

Clin Biochem. 2004 Jun;37(6):424-8. Review.

PMID:
15183289
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk